Zafirlukast: A Comprehensive Guide for Respiratory Health

What is Zafirlukast?

Zafirlukast is a medication belonging to the class of drugs known as leukotriene receptor antagonists (LTRAs). It is primarily prescribed to manage and prevent chronic asthma in adults and children. By blocking the action of leukotrienes, inflammatory substances naturally produced by the body, Zafirlukast helps to reduce airway inflammation, smooth muscle contraction, and mucus production, which are key components in the pathophysiology of asthma. While it is effective in controlling persistent asthma symptoms, it is not intended for the immediate relief of acute asthma attacks. Zafirlukast is available in both generic forms and under the brand name Accolate, offering a vital therapeutic option for individuals seeking long-term management of their respiratory condition.

Mechanism of Action

Zafirlukast exerts its therapeutic effects by selectively and competitively inhibiting the binding of cysteinyl leukotrienes (CysLTs) to their specific receptors, primarily the CysLT1 receptor. Leukotrienes, such as LTC4, LTD4, and LTE4, are potent lipid mediators derived from arachidonic acid metabolism. In the context of asthma and other inflammatory respiratory conditions, these molecules play a crucial role in initiating and perpetuating the inflammatory cascade within the airways. Upon binding to the CysLT1 receptor, leukotrienes trigger a series of events:

• Bronchoconstriction: They cause the smooth muscles surrounding the airways to contract, leading to narrowing of the bronchial passages.
• Increased Vascular Permeability: This contributes to airway edema (swelling).
• Mucus Hypersecretion: They stimulate goblet cells to produce excessive amounts of mucus, further obstructing the airways.
• Inflammatory Cell Infiltration: They attract and activate inflammatory cells, such as eosinophils and T lymphocytes, to the site of inflammation, perpetuating the chronic inflammatory state characteristic of asthma.

By acting as an antagonist at the CysLT1 receptor, Zafirlukast effectively blocks these downstream effects. It prevents leukotrienes from binding to their receptors, thereby inhibiting bronchoconstriction, reducing airway inflammation, decreasing mucus production, and mitigating the influx of inflammatory cells. This multifaceted action helps to improve lung function, reduce the frequency and severity of asthma exacerbations, and alleviate symptoms such as wheezing, shortness of breath, and chest tightness. Unlike bronchodilators, Zafirlukast addresses the underlying inflammatory processes of asthma rather than providing immediate symptom relief.

Clinical Uses & Indications

The primary indication for Zafirlukast is the long-term management of chronic asthma in patients aged 5 years and older. It is particularly beneficial for individuals whose asthma is not adequately controlled by other standard therapies, such as inhaled corticosteroids or short-acting beta-agonists. Zafirlukast helps to prevent the daily symptoms of asthma and reduce the frequency of asthma exacerbations.

FDA-Approved Uses:

• Chronic Asthma: Zafirlukast is FDA-approved for the maintenance treatment of chronic asthma in both adults and pediatric patients aged 5 years and older. It aims to improve lung function and reduce the need for rescue medications.
• Exercise-Induced Bronchoconstriction (EIB): In some cases, Zafirlukast may be used to prevent bronchoconstriction that occurs as a result of physical exertion. It is typically taken two hours before exercise for this purpose.

It is crucial to understand that Zafirlukast is a controller medication and should be taken consistently as prescribed, even when symptoms are absent. It does not provide rapid relief from acute bronchospasm or asthma attacks. Patients experiencing an acute attack should use their rescue inhaler (e.g., albuterol) as directed by their healthcare provider.

Dosage & Administration

Zafirlukast is administered orally, typically in tablet form. The dosage and frequency depend on the patient's age, weight, and the severity of their condition. It is essential to follow the prescribing physician's instructions precisely.

Common Dosage Regimen:

• Adults and Children 12 Years and Older: The usual dose is 20 mg taken orally twice daily.
• Children 5 to 11 Years Old: The usual dose is 10 mg taken orally twice daily.

Important Administration Considerations:

• Timing: Zafirlukast should be taken approximately one hour before or two hours after meals. Food can affect the absorption of the drug, potentially reducing its efficacy.
• Consistency: For optimal benefit in chronic asthma management, Zafirlukast should be taken at regular intervals, as prescribed, even during periods of symptom remission.
• EIB Prevention: When used for exercise-induced bronchoconstriction, Zafirlukast is typically taken two hours prior to exercise. It should not be taken more than once within a 24-hour period for this indication.

Patients should be instructed not to discontinue Zafirlukast or alter their dosage without consulting their healthcare provider, even if their symptoms improve. If a dose is missed, it should be taken as soon as remembered, unless it is close to the time for the next scheduled dose. In such cases, the missed dose should be skipped, and the regular dosing schedule resumed.

Side Effects & Safety

Like all medications, Zafirlukast can cause side effects, although not everyone experiences them. The majority of side effects are mild to moderate, but some serious reactions require immediate medical attention.

Common Side Effects:

• Headache
• Nausea
• Diarrhea
• Abdominal pain
• Dizziness
• Fatigue
• Rash

Serious Side Effects and Warnings:

• Hepatotoxicity: Zafirlukast has been associated with liver damage, including elevated liver enzymes and, in rare cases, severe hepatic events such as hepatitis and liver failure. Symptoms may include jaundice (yellowing of the skin or eyes), dark urine, severe abdominal pain, nausea, and vomiting. Patients with pre-existing liver disease should use Zafirlukast with caution. Regular monitoring of liver function tests may be recommended.
• Churg-Strauss Syndrome (CSS): Zafirlukast, along with other LTRAs, has been linked to a rare but serious systemic eosinophilic vasculitis, known as Churg-Strauss Syndrome. Patients experiencing symptoms such as asthma worsening, new or worsening shortness of breath, new or worsening cough, chest pain, heart problems, numbness or tingling in the extremities, or rash should seek immediate medical attention.
• Neuropsychiatric Events: Although less common, Zafirlukast has been associated with neuropsychiatric effects, including mood changes, depression, anxiety, agitation, and, rarely, suicidal thoughts or behavior. Patients with a history of psychiatric disorders should be closely monitored.
• Allergic Reactions: Severe allergic reactions (anaphylaxis) can occur, characterized by hives, difficulty breathing, swelling of the face, lips, tongue, or throat.

Contraindications:

• Zafirlukast is contraindicated in patients with known hypersensitivity to the drug or any of its components.
• It is also contraindicated in patients with severe hepatic impairment.

It is crucial for patients to discuss their complete medical history, including any liver conditions or psychiatric disorders, with their healthcare provider before starting Zafirlukast. Prompt reporting of any new or worsening symptoms is essential for safe and effective management.

Drug Interactions

Zafirlukast can interact with several other medications, potentially altering their effectiveness or increasing the risk of side effects. Careful consideration of these interactions is vital for patient safety.

Notable Drug Interactions:

• Theophylline: Zafirlukast can inhibit the metabolism of theophylline, a bronchodilator. This can lead to increased serum concentrations of theophylline, potentially causing toxicity. If co-administration is necessary, theophylline levels should be closely monitored, and its dosage may need to be adjusted.
• Warfarin: Zafirlukast can increase the prothrombin time (PT) and the international normalized ratio (INR) in patients taking warfarin, an anticoagulant. This increases the risk of bleeding. Patients on warfarin therapy should have their PT/INR monitored closely when starting or stopping Zafirlukast, and warfarin dosage adjustments may be required.
• Aspirin: Concurrent administration of Zafirlukast with aspirin has been shown to increase the plasma concentration of Zafirlukast. While the clinical significance of this interaction is not fully established, it may necessitate dose adjustments of Zafirlukast.
• CYP1A2 Substrates: Zafirlukast is a moderate inhibitor of the cytochrome P450 enzyme CYP1A2. Therefore, it may increase the plasma concentrations of other drugs metabolized by CYP1A2, such as certain antidepressants (e.g., fluvoxamine) and antipsychotics. Caution and potential dose adjustments of these concomitant medications may be warranted.

Patients should always inform their healthcare provider about all medications they are currently taking, including prescription drugs, over-the-counter medicines, and herbal supplements, to identify and manage potential drug interactions effectively.

Molecular Properties

Understanding the molecular characteristics of Zafirlukast is fundamental to comprehending its pharmacological behavior and interactions.

Key Molecular Data:

• Molecular Formula: C20H23N3O3S
• Molecular Weight: 377.48 g/mol
• SMILES Notation: COc1cc2cc(NC(=O)OC3CCCC3)c(cc2cc1C(C)C)CS(=O)(=O)c1cccc2ccncc12

Structure Description: Zafirlukast is a synthetic molecule characterized by a quinoline ring system and a sulfonyl group. The core structure includes a methoxy-substituted benzene ring fused to a pyridine ring, forming the quinoline moiety. Attached to this quinoline system is an isopropyl group and a carbamate linkage. The carbamate group connects to a cyclopentyl ring. A key feature is the presence of a benzenesulfonyl group, which is further substituted with a fused bicyclic system containing a pyridine ring. The sulfonyl group (SO2) plays a role in the molecule's interaction with the leukotriene receptor. The precise arrangement of these functional groups dictates Zafirlukast's affinity and selectivity for the CysLT1 receptor, enabling it to act as an antagonist.

The SMILES (Simplified Molecular Input Line Entry System) string, COc1cc2cc(NC(=O)OC3CCCC3)c(cc2cc1C(C)C)CS(=O)(=O)c1cccc2ccncc12, provides a concise, text-based representation of Zafirlukast's chemical structure. This notation allows for unambiguous identification and computational manipulation of the molecule, facilitating its analysis in drug discovery and development processes.

Analyze Zafirlukast with MolForge

Exploring the intricacies of Zafirlukast, from its molecular structure to its pharmacological profile, is essential for researchers and drug developers aiming to advance respiratory therapeutics. MolForge's AI-powered platform offers an unparalleled environment to delve deeper into molecules like Zafirlukast. Utilize our advanced tools to analyze its properties, predict potential interactions, explore structure-activity relationships, and accelerate your discovery pipeline. Discover new therapeutic avenues and optimize existing drug candidates by leveraging the power of artificial intelligence. Visit our dashboard to begin your molecular exploration today.